Prescient Therapeutics CEO James McDonnell talked with Proactive about promising developments surrounding the company’s lead asset, PTX-100, in its treatment of cutaneous T-cell lymphoma (CTCL). The therapy has shown compelling results from its Phase 1B trial, with a 64% clinical benefit rate and no serious adverse events – outperforming internal benchmarks.
McDonnell explained, “We saw that CTCL patients had the most response, so we’re prioritising them in Phase 2A for a quicker, more cost-effective path.” The company has now dosed its first patient in the Phase 2A study, marking a key step forward.
PTX-100 has also secured orphan drug and fast track designations from the FDA. McDonnell highlighted the significance of these approvals, stating they enable an expedited pathway for patients with unmet needs and could offer seven years of market exclusivity upon approval.
The company is targeting a total addressable market of $1.80 billion across T-cell lymphomas, with a clear focus on the $600 million CTCL segment via FDA registration. Investigator-led programs will support entry into additional indications.
Looking further ahead, McDonnell noted that the underlying cancer pathway PTX-100 targets is implicated in 22% of cancers, opening up future potential in tumor types like lung, colon, and pancreatic cancers.
Visit Proactive's YouTube channel for more company updates and executive interviews. Don’t forget to like this video, subscribe to the channel, and enable notifications for future content.
#PrescientTherapeutics #PTX100 #CancerTreatment #TCellLymphoma #BiotechNews #OncologyResearch #FDAFastTrack #OrphanDrug #ClinicalTrials #CancerInnovation #HealthcareInvesting #ProactiveInvestors